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A B S T R A C T   
The incidence of Neonatal Abstinence Syndrome (NAS) continues to rise and there remains a critical need to 
develop non-pharmacological interventions for managing opioid withdrawal in newborns. Objective physiologic 
markers of opioid withdrawal in the newborn remain elusive. Optimal treatment strategies for improving short- 
term clinical outcomes and promoting healthy neurobehavioral development have yet to be defined. This dual- 
site randomized controlled trial (NCT02801331) is designed to evaluate the therapeutic efficacy of stochastic 
vibrotactile stimulation (SVS) for reducing withdrawal symptoms, pharmacological treatment, and length of 
hospitalization, and for improving developmental outcomes in opioid-exposed neonates. Hospitalized newborns 
(n = 230) receiving standard clinical care for prenatal opioid exposure will be randomly assigned within 48- 
hours of birth to a crib with either: 1) Intervention (SVS) mattress: specially-constructed SVS crib mattress 
that delivers gentle vibrations (30–60 Hz, ~12 μm RMS surface displacement) at 3-hr intervals; or 2) Control 
mattress (treatment as usual; TAU): non-oscillating hospital-crib mattress. Infants will be studied throughout 
their hospitalization and post discharge to 14-months of age. The study will compare clinical measures (i.e., 
withdrawal scores, cumulative dose and duration of medications, velocity of weight gain) and characteristic 
progression of physiologic activity (i.e., limb movement, cardio-respiratory, temperature, blood-oxygenation) 
throughout hospitalization between opioid-exposed infants who receive SVS and those who receive TAU. 
Developmental outcomes (i.e., physical, social, emotional and cognitive) within the first year of life will be 
evaluated between the two study groups. Findings from this randomized controlled trial will determine whether 
SVS reduces in-hospital severity of NAS, improves physiologic function, and promotes healthy development.   
1. Introduction 
Opioid-use during pregnancy and post-natal effects on the neonate 
continues to be a growing and costly public health problem [1–5]. 
Particularly alarming is the high rate of use and misuse of prescription 
opioids, with reports of use of these extremely addictive narcotic pain 
Abbreviations: EMR, Electronic Medical Record; NAS, Neonatal Abstinence Syndrome; UMass, UMass Memorial Healthcare (Coordinating/Primary study site); 
UPitt, University of Pittsburgh (Consortium study site); NICU, Neonatal Intensive Care Unit; NN, Newborn Nursery; SVS, Stochastic vibrotactile stimulation 
(intervention-mattress condition); TAU, Treatment as usual (control condition). 
* Corresponding author. Department of Psychiatry University of Pittsburgh School of Medicine, 3501 Forbes Avenue, Pittsburgh, PA, 15213, USA. 
E-mail address: salisburye2@upmc.edu (E. Bloch-Salisbury).   
1 Current address: Department of Psychiatry, University of Pittsburgh School of Medicine, 3501 Forbes Avenue, Pittsburgh, PA, 15213. 
Contents lists available at ScienceDirect 
Contemporary Clinical Trials Communications 
journal homepage: http://www.elsevier.com/locate/conctc 
https://doi.org/10.1016/j.conctc.2021.100737 
Received 2 October 2020; Received in revised form 12 January 2021; Accepted 29 January 2021   
Contemporary Clinical Trials Communications 21 (2021) 100737
2
medications during pregnancy ranging between 5% and 42% [4,6]. 
Latest reports show that on average 8 of every 1000 hospital-born 
newborns nationwide are diagnosed with withdrawal from opioid 
exposure in utero, which translates to approximately 4 infants per hour 
[5]. In the United States, annual hospitalization costs to treat 
opioid-exposed newborns are estimated at over half a billion dollars and 
this does not include care after discharge [3]. Infants exposed to opioids 
prenatally develop physical tolerance and dependence through 
placental transfer [7,8]. The abrupt cessation of such substances that 
occurs at birth when the infant’s blood supply becomes independent of 
their mother’s results in a wide range of withdrawal symptoms and 
dysregulated behaviors that vary in severity from minimal to life 
threatening, commonly referred to as Neonatal Abstinence Syndrome 
(NAS) or Neonatal Opioid Withdrawal Syndrome [8–11]. 
Clinically significant neurobehavioral symptoms of NAS include 
pathophysiologic cardio-respiratory instabilities, gastrointestinal 
dysfunction, and hyperirritability [9,12,13]. Despite first-line non--
pharmacological management strategies to help reduce withdrawal (e. 
g., breastfeeding, skin to skin, swaddling, and rooming-in) [14–16], 
many opioid-exposed newborns require prolonged hospitalization to 
treat withdrawal with federally-controlled opioid agonists (e.g., 
morphine, methadone, buprenorphine) [10,17–20] and other prescribed 
medications (phenobarbital, clonidine) [18,21]. Animal and human 
studies suggest pharmacological interventions used to treat withdrawal 
may have independent, additive, or synergistic detrimental conse-
quences on development such as impaired motor activity, altered noci-
ceptive responses to pain including hyperalgesia, and may contribute to 
cognitive deficits and behavioral problems [22–26]. Treatment pro-
tocols for NAS that incorporate non-pharmacological strategies remain 
largely unexplored [15,27–29]. Non-pharmacologic, complementary 
therapeutic strategies are needed to reduce symptoms and severity of 
withdrawal, facilitate weaning, and reduce cumulative and prolonged 
exposure to pharmacologic agents, particularly among infants for whom 
first-line supportive care [14,15] is insufficient or not feasible. 
Stochastic resonance-based techniques have been used to promote 
stability in destabilized biological systems – by introducing artificial 
noise in the form of low-level, stochastic (i.e., random, noisy) stimula-
tion a destabilized sensory system can be converted to normal rhythms 
[30,31]. In a single-session study, stochastic vibrotactile stimulation 
(SVS) delivered through a specially-constructed crib mattress [32] 
improved cardio-respiratory rhythms and reduced irritability in a small 
cohort of full-term infants with NAS [29]. The primary aim of the cur-
rent trial is designed to test mattress SVS as a therapeutic strategy for 
regulating destabilized systems in opioid-exposed newborns. This study 
will assess effects of SVS mattress stimulation throughout infant hospi-
talization on short-term clinical outcomes and post-discharge re-hospi-
talization, morbidities, and neurobehavioral development [15,33]. 
Despite the growing problem of neonatal opioid exposure, objective 
physiologic markers of withdrawal in the newborn remain elusive. A 
second interdependent aim of this study is to assess pathophysiologic 
instabilities of withdrawal using quantifiable autonomic signals (e.g., 
cardiac, respiratory, temperature) and assess the effects of SVS on these 
physiologic measures. Movement activity, an index of irritability, will 
also be quantified throughout infant’s hospitalization using acitgraphy 
[34]. These objective measurements will provide insight into the pro-
gression of physiologic withdrawal in hospitalized opioid-exposed 
newborns and provide quantifiable physiologic effects of the SVS 
intervention. 
In this randomized, controlled clinical trial, Efficacy and Outcomes of 
a Non-Pharmacological Intervention for Neonatal Abstinence Syndrome 
(NCT02801331), we will study SVS complementary to standard of care 
for treating hospitalized opioid-exposed newborns. Using specially- 
constructed crib mattresses [32] we will determine if SVS reduces 
symptoms and duration of withdrawal, improves autonomic function, 
and enriches long term developmental outcomes in full-term, intra-
uterine opioid-exposed newborns compared to those receiving standard 
of care with hospital-issued, non-oscillating crib mattresses. This 
dual-site study funded by National Institute on Drug Abuse 
(R01DA042074; Bloch-Salisbury) is being conducted at UMass Memo-
rial Healthcare (UMass, Worcester, MA; coordinating and primary site; 
Principal Investigator Bloch-Salisbury) and at the University of Pitts-
burgh (UPitt; Pittsburgh, PA; consortium site, Principal Investigators 
Bogen and Beers). 
2. Materials and methods 
2.1. Objectives 
The objective of this trial is to assess efficacy and outcomes of SVS 
delivered through a crib mattress as a complementary therapeutic 
intervention for NAS. The study will compare clinical characteristics, 
progression of physiologic withdrawal, and developmental outcomes 
among opioid-exposed newborns receiving treatment as usual (TAU) 
and those receiving TAU plus a novel SVS-mattress intervention aimed 
at reducing NAS course and impairments. Short-term clinical outcomes, 
withdrawal symptomatology, and physiologic responses will be assessed 
throughout infants’ hospitalization. Longitudinal assessments post- 
discharge will test whether SVS-mattress intervention improves infant 
physical, social, emotional and cognitive development in the first year of 
life. 
2.1.1. Hypothesis 
The primary hypothesis of this study is that complementary SVS- 
mattress intervention throughout neonatal hospitalization provides so-
matosensory perturbations that improve central and autonomic control, 
indexed by reductions in pathophysiologic instabilities and better short- 
term clinical and longitudinal developmental outcomes, compared to 
TAU alone. To test this, we will quantify and compare the following 
between infants receiving daily intervals of SVS-mattress intervention 
and infants receiving only TAU:  
1) Clinical variables throughout hospitalization will include range and 
trajectory of withdrawal severity scores (Finnegan [27,35]), medi-
cation to treat withdrawal (duration; cumulative dose), velocity of 
weight gain, and hospital length of stay. Movement activity 
measured with actigraphy will be used to index irritability 
throughout hospitalization. Full-physiologic assessments of with-
drawal, including cardiac and respiratory activity, movement ac-
tivity, blood-oxygenation and thermoregulation, will be studied in a 
sub-cohort of infants receiving pharmacologic management in the 
neonatal intensive care unit (NICU) on two single-session study days; 
and  
2) Post hospital discharge, infant developmental outcomes will be 
assessed up to 14-months of age, controlling for general environ-
mental and family function, and maternal cognitive ability. Trained 
study staff will obtain bi-monthly developmental report from the 
infant’s caregiver and will conduct validated, comprehensive 
developmental assessments with the infant at 6 mos and 12 mos. 
2.2. Trial design 
This study is a prospective dual site, randomized controlled parallel- 
group trial with two arms: (1) Intervention (SVS); SVS mattress; (2) 
Control (TAU); hospital-issued non-oscillating mattress. Masking of 
bedside caregivers (family and medical) and research staff from condi-
tion assignment is not feasible due to the vibrating-mattress apparatus 
(Fig. 1) and physical output of the stimulation. Outcomes personnel who 
conduct the follow-up assessments will be masked to subject’s 
randomized-condition assignment. 
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2.3. Study participants and setting and participants 
A total of 230 infant-mother dyads will be recruited over a 4-year 
period with follow-up assessments extending through a 5th year of the 
project. In-hospital bedside studies will be conducted at UMass Memo-
rial Healthcare (UMMHC) Memorial Campus, Worcester MA (UMass 
site) in the NICU (including Continuing Care Nursery) and Newborn 
Nursery (NN), and at the consortium site (UPitt) at UPMC Magee- 
Women’s Hospital, Pittsburgh PA, in the NICU and NN Mother-Baby and 
Parent Partnership Units, where subjects receive round-the-clock med-
ical care. In-person follow-up assessments will be conducted at UMass 
study-staff office and UPitt outpatient-research clinic. Outcomes as-
sessments may also be performed at the subject’s home for participants 
with transportation limitations. 
Written informed consent will be obtained from the biological 
mother of each infant either prenatally or within 48 h after delivery for 
their and their infant’s participation in the study. In instances where 
infants are placed in state custody by the Department of Children and 
Families (MA) or Children, Youth and Family Services (PA) and the 
biological mother retains parental rights to continue participation in the 
study, the state-assigned caregivers may also be enrolled to participate 
in the infant follow-up assessments in accordance with respective state 
and Institutional policies. Infants for whom parental rights have been 
terminated by the courts after study enrollment will be withdrawn from 
study upon notification of termination. 
The study was approved by the UMass Medical School Institutional 
Review Board (IRB), which serves as the IRB of record through a reliance 
agreement with UPitt. A NIH Certificate of Confidentiality was obtained 
for this study to protect subjects from disclosures and ensure confiden-
tiality of information. We obtained a Prisoner Certification to allow 
biological mothers who meet the regulatory definition of prisoner but 
are not detained in a penal institution to participate in the study. Study 
enrollment started March 2017. Data collection is expected to be 
completed by the end of 2021. 
2.4. Eligibility and Exclusion Criteria 
Eligibility Criteria: Eligible participants are full-term, newborn in-
fants (≥37 weeks gestational age) at risk for NAS due to opioid exposure 
in utero and receiving care in the NICU or NN at UMass or at UPitt. At- 
risk is defined as infants who present with confirmed meconium and/ 
or urine toxicology report and/or documented medical record for one or 
more in-utero opioid exposures (e.g., methadone, buprenorphine, oxy-
codone, heroin). Infants may have additional prenatal exposure to other 
drugs (legal or illicit use, including but not limited to benzodiazepines, 
barbiturates, amphetamines, cannabinoids, cocaine, alcohol, nicotine). 
Exclusion Criteria: Infants are excluded from study participation if 
born less than <37 weeks or having any of the following medical con-
ditions: one or more clinically significant congenital anomalies, hyo-
drocephalus, intracranial hemorrhage > grade 2, neonatal seizures not 
related to drug withdrawal, anemia with hgB<8.0 g/dl, hypoxic- 
ischemia encephalopathy, respiratory failure requiring invasive venti-
latory support, or receiving treatment for bacterial or other viral con-
ditions. Infants can also be excluded if not approved for study by their 
attending physician. 
2.5. Study device: mattress stochastic vibrotactile stimulation (SVS) 
The SVS mattresses employed in this study are experimental devices 
(non-commercially available), not approved by the U.S. Food and Drug 
Administration as a treatment for NAS. The mattresses were constructed 
by engineers at the Wyss Institute at Harvard University and Cofab 
Design, LLC using patent specifications [32]. Device components may be 
modified during the study trial with improved technologies that provide 
equivalent mattress output to help ensure consistency of mattress 
integrity. Each trial mattress was individually constructed with the same 
dimensions (23′′x12′′x3′′) to fit into the standard hospital crib 
(26′′x14′′x8′′) and to provide whole-body SVS (30–60 Hz, ~12 μm RMS 
centrally maximized with near-linear surface displacement; Wyss Insti-
tute, Harvard University; Cofab Design, LLC [32]). They were designed 
so that the foam vibrates throughout the entire mattress (as depicted in 
Fig. 1) to gently stimulate the infant, analogous to prototype mattresses 
Fig. 1. Stochastic vibrotactile stimulation (SVS) mattress device.  
E. Bloch-Salisbury et al.                                                                                                                                                                                                                       
Contemporary Clinical Trials Communications 21 (2021) 100737
4
used in other short-term studies [1,29]. The UMMHC Biomedical Engi-
neering and the UPMC Magee-Womens Hospital Clinical Engineering 
departments will provide annual certification of the electrical safety of 
the mattress devices. Engineers at UPitt, Wyss Institute, and Cofab 
Dsign, LLC will routinely test and calibrate mattresses to ensure integrity 
is maintained throughout the project period. 
2.6. Procedures 
Fig. 2 provides a schematic of the target enrollments and subject 
participation in the study interventions and assessments for each site 
over the 5-year period. We created a study manual of operations that 
research staff are trained to follow to ensure both sites follow the same 
code of conduct, which details all areas of the study project described 
below. The lead principal investigator (PI; EBS) will travel between sites 
to initially assist with setting up infrastructure and training of study staff 
and thereafter to help ensure consistency in protocol administration and 
data collection, and device integrity. Throughout the trial, research staff 
will participate in routine dual-site conference calls to review proce-
dural issues, progress and problems, and to promote ongoing collabo-
ration with the interdisciplinary team of investigators. 
2.6.1. Recruitment 
Infants at risk for NAS due opioid exposure in utero will be pre-
screened for eligibility using a HIPAA waiver through electronic medical 
records (EMR) or may be identified to investigators by medical care-
givers. Infants will be recruited either prenatally in the obstetrical clinics 
and prenatal clinics for pregnant women with opioid-use disorder, or 
post-delivery in NICU, NN and Mother-Baby Units. Upon permission 
from an attending or primary medical-caregiver responsible for the in-
fant’s care, the biological mother will be approached for informed 
consent by a research investigator with consenting privileges and in 
accordance with IRB and respective state regulations. 
2.6.2. Randomization 
Infants will be randomized and assigned to either (1) Intervention 
group (SVS) or (2) Control group (TAU). Randomization is performed by 
assigned research personnel through an automated, audited-password 
protected program developed and administered by the Department of 
Population and Quantitative Health Science at UMass. The program was 
designed separately for the UMass and UPitt sites. Male and female 
subjects will be separately randomized using a modified force-block 
design allocating a maximum of 6 assignments for a given period (i.e., 
up to 3 SVS assignments and 3 TAU assignments) to help ensure even 
allocation of the intervention for each site and within each gender. 
Given the unknown and varying length of stay for each participant, the 
intervention assignment is returned to the randomization pool upon the 
infant’s hospital discharge to maximize assignment of eligible candi-
dates. Only 3 SVS mattresses and 3 TAU assignments will be allocated 
for randomization; additional mattresses are available to replace mat-
tresses should they become inoperable within a study period or fail 
integrity-calibration tests. No more than 6 infants will be enrolled in 
each hospital site at a given time; recruitment will be paused should this 
limit be reached and resume upon infant discharge from hospital, 
opening a SVS or TAU assignment.  
(1) SVS. For infants assigned to the SVS mattress, the hospital crib 
mattress will be replaced with the specially constructed mattress 
to provide gentle vibrations during mattress stimulation periods 
(Fig. 1). Infants will receive daily interventions of continuous 
intervals of SVS throughout hospitalization while in the crib. The 
device is designed to automatically cycle on and off at 3-hour 
intervals. Infants are not always in their crib (e.g., held by care-
giver, feeding, bathing, placed in other hospital-issued infant 
seats – all part of the standard of care) and it is not feasible to 
provide round-the-clock research staffing to monitor when the 
infant is in or out of their crib. The pre-programmed 3-hr duty 
cycle, 24/7, affords opportunity to capture periods when the in-
fant is in the crib and also conforms to routine timing of medi-
cation at both sites. The mattress stimulation will cycle on and off 
even if the infant is not in his/her crib. An uninterrupted battery 
supply will be placed on a crib shelf or rolling-cart alongside the 
crib to help ensure continuous duty cycle when infants are moved 
in the units, such as between nursery and maternal rooms. The 
start and stop times of the mattress cycle will vary among subjects 
as a function of initial enrollment time. The mattress duty-cycle 
times, including initial start and any subsequent stop/restart 
times, and routine calibration of mattress integrity will be 
documented in the study data base.  
(2) TAU. Infants randomized to this arm will be assigned to the 
standard, non-oscillating hospital crib mattress throughout hos-
pitalization and will not receive any periods with the mattress 
SVS. 
2.6.3. Infant daily assessments throughout hospitalization 
Infants will be enrolled within 48-hours post birth. Infants at both 
Fig. 2. Target enrollment plan. SVS=Stochastic vibrotactile stimulation mattress (intervention); TAU = Treatment as usual (control).  
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sites are typically observed clinically for signs and symptoms of with-
drawal [27,35] in the NN/Mother-Baby Units for 4–7 days. Infants who 
warrant pharmacologic treatment for severity of withdrawal based on 
common conventional clinical protocol [36] are transferred to the NICU. 
Regardless of randomization assignment, all infants will receive 
respective site standard of care (e.g., unit assignments, 
clinically-determined pharmacotherapy). Caregivers (medical and 
family) will be instructed to care for the infant-subject as they typically 
would do, including feeding, holding, unit volunteer trained Cuddlers, 
or placing the infant in hospital-issued motorized seats, independent of 
assignment. 
To help ensure safety of infants assigned to the SVS mattress inter-
vention, if the infant does not show significant signs of withdrawal 
during the first few days of life (i.e., not transferred to NICU for phar-
macotherapy), the mattress intervention will be turned off 12–24 h 
before anticipated discharge from NN to home to allow medical care-
givers to observe the infant without the stimulation prior to hospital 
discharge. Should the infant exhibit signs of withdrawal that the medical 
team determines warrants medication to treat, the infant will be trans-
ferred to the NICU as per standard of care and the SVS will resume as per 
study protocol, cycling every 3 h until the infant’s medication is stopped. 
At both sites, this is typically about 24–48 h before the infant is dis-
charged to home. 
For all infant participants, research staff will record routine cares and 
daily clinical assessments obtained from EMR into the study data base, 
including feed type, route and amount (i.e., breastmilk or formula, 
breast fed or bottle and duration and volume respectively), and infant 
weight. Standard clinical-care withdrawal scores [27,35] and pharma-
cological treatment will be recorded throughout the course of the in-
fant’s hospitalization and factored into the analyses. 
In addition to assessing standard clinical measures of withdrawal 
throughout hospitalization, this study will use actigraphy as a novel 
approach to obtain an objective assessment of infant “irritability.” 
Actigraphy is a simple, non-invasive tool that measures movement ac-
tivity. Only a few, small studies have used it to assess severity of 
neonatal withdrawal (e.g., Ref. [34]) including a pilot study by our 
group [37].To provide a quantifiable measure of irritability, a small, 
lightweight actigraphy sensor (Philips Actiwatch 2, Respironics, Mur-
raysville, PA) will be worn around the infant’s lower leg using a soft, 
foam band throughout hospitalization. The location of the sensor on the 
leg will be alternated to protect against skin irritation. The actigraphy 
data will be routinely downloaded into the study data base. Movement 
activity will be assessed during periods when the infant is in the crib 
when the mattress is vibrating (SVS ON) and when the mattress is OFF 
(SVS OFF), allowing for comparisons between periods of SVS ON and 
SVS OFF with infants assigned to the SVS mattress and with infants 
assigned to TAU (i.e., SVS OFF). 
Caregivers (i.e., family and medical) will be instructed to use a 
computerized study log at the infant’s bedside to record infant’s daily 
bedside activities, including time the infant is in the crib, being held or 
fed, in hospital-issued motorized seats (standard of care), and routine 
nursing cares. Fig. 3 illustrates bedside set-up, including the bedside 
computerized log and mattress setup. 
2.6.4. Infant single-session physiologic assessments in-hospital 
To further explore objective indices of withdrawal, a subset of infants 
at the UMass site who receive pharmacotherapy for withdrawal may 
participate in 1–2 full-physiology recording sessions during their hos-
pitalization in the NICU. These sessions will last approximately 8–12 h, 
conducted approximately between 6am and 6pm. To better understand 
the physiology of withdrawal in newborns, controlling for time from 
birth, subjects will be studied between 5 and 7 days old, and between 12 
and 14 days old. Infants will be studied in their unit bedside crib in 
accordance with their original study randomization assignment (SVS, 
using the infant’s same 3-hour ON/OFF duty cycle on the study day; or 
TAU, no stimulation). During these sessions, additional sensors will be 
applied to the infant analogous to our previous studies [29,38]. 
Continuous cardiac, respiratory, blood-oxygenation, axillary tempera-
ture and movement activity (duration and frequency) will be recorded 
throughout the session day to quantify physiologic markers of opioid 
withdrawal among infants at the same age of life. Physiology will be 
compared between periods of SVS ON and SVS OFF with infants assigned 
Fig. 3. Bedside Setup. SVS group = Infants 
randomly assigned to receive stochastic 
vibrotractile stimulation: SVS mattress in 
bedside portable crib with stimulus driver 
and uninterrupted power supply in crib-cart 
shelving; TAU group = Infants randomly 
assigned to receive treatment as usual (hos-
pital crib mattress, not shown); Touchscreen 
computerized bedside log with laminated 
instructions attaches to crib; Mattress proto-
col indicates automated 3-hour stimulation 
cycle (SVS) or no stimulation (TAU).   
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to the SVS mattress, and between infants assigned to SVS and TAU. 
2.6.5. Infant follow-up assessments post hospital discharge 
Following hospital discharge, infants will be followed throughout 
their first year of life. Phone-call follow-up using a brief (approximately 
10–15 min) standardized interview script will begin 1 week after 
discharge to determine any hospital readmission as well as to obtain a 
general assessment of behaviors and home environment. Assessments 
will continue bi-monthly throughout the year up until the infant is no 
more than 14 mos of age. Report of infant’s development will also be 
obtained from the caregiver using the Ages and Stages Questionnaires 
[39] by trained study staff starting at the 4-mos phone call. Bi-monthly 
phone calls are also incorporated to help keep subjects engaged in the 
study and to promote subject retention for the in-person neuro-
development assessments. 
Infants will participate in comprehensive developmental assessments 
at approximately 6 mos and 12 mos of age (see Section 2.10 Outcomes 
and Table 1 for detailed description of these assessments). Infants will be 
assessed either on site or at home visits. Each in-person visit will last 
approximately 2 h and include self-report questionnaires about the in-
fant by the caregiver. Trained neuropsychologists or developmental 
specialists trained and supervised by an experienced neuropsychologist 
(SRB) will administer and score the neurodevelopment tests. For quality 
assurance, the Pitt site principal investigator (SRB) who is a trained 
neuropsychologist and/or the senior developmental specialists (CB/EE) 
will review test protocols at both sites for valid administration and 
scoring. Development specialists will participate in routine joint- 
training sessions and conference calls to ensure both sites are consis-
tently following protocol, and to problem solve any subject issues and 
examiner drift that may arise. 
2.6.6. Maternal assessments 
Biological mothers who consent to participate with their infant will 
complete a maternal questionnaire that includes information not avail-
able in the EMR, including detailed history of drug use before and 
throughout pregnancy. Biological mothers will also complete self-report 
questionnaires that provide a general evaluation of family relationships 
(McMaster Family Assessment Device [40]) and psychological distress 
(Brief Symptom Inventory [41]) reflective of the week preceding the 
birth of their infant, and at the infant’s 6 mos and 12 mos assessment. A 
general index of the biological mother’s cognitive and perceptual/rea-
soning skills will be assessed with the Wechsler Abbreviated Scale of 
intelligence –Second Edition (WASI-II) [42] at a separate visit within the 
1-year study period, typically within the first few months of the study. 
2.7. Measures to retain subjects and minimize missing data 
Study staff will provide in-service to nursing staff at respective sites 
to explain study protocol and demonstrate bedside study equipment. 
Medical caregivers will not be responsible for managing any of the 
bedside study equipment but will be trained to assist in marking infant 
activity using the computerized bedside study log. To reduce loss of data 
due to technical issues, research staff contact information will be clearly 
labelled on the bedside equipment and study staff will be on call 24-7 to 
troubleshoot by phone or in person any issues with the bedside devices. 
Study staff will check on infants and study equipment daily throughout 
the infant’s hospitalization. Frequent communication by study staff with 
subjects and medical caregivers, and daily checks at the hospital bedside 
of the infant and study equipment will facilitate rapport with subjects 
and medical staff caring for the infants. This will help ensure any con-
cerns about infant participation are communicated and that study de-
vices are working properly throughout the study period. Follow-up and 
retention is facilitated by detailed contact information including alter-
nate contacts who may also participate in the follow-up assessments, by 
routine bi-monthly telephone assessments, incorporation of home visits 
for families with limited access to transportation, parking vouchers for 
Table 1 
List of assessments.  
Task (time) 
Testing Age 
Description and Respondent 
[Child (C) or Parent (P)] 
Key Variables 
FUNCTIONAL STATUS OF INFANT 
GOS-E Peds [64] (10 
min) 
1mo*, 6mo, and 12mo 
The 8 GOS-E Peds categories 
track recovery of function 
between groups. This version 
includes semi-structured 
interview questions relevant to 
infants. Administered by 
Outcomes Specialist. (C, P). 
Category Score 
(1–8) 
Pediatric Quality of 
Life [65] (5 min) 
6mo and 12mo 
The PedsQL Parent Report for 
Infants, age ranges from 1 to 12 
months and 13–24 months. 
Scales assess physical function, 
physical symptoms, emotional 
function, social function, and 
cognitive function. Administered 
by Outcomes Specialist or 
Research Study Staff. (P) 
Total Score 
Subscale Scores 
NEURODEVELOPMENT AND SLEEP STATUS OF INFANT 
Bayley Scales of Infant 
& Toddler 3rd Ed 
[45]. (30 min) 
6mo and 12mo 
The Bayley III measures 
neurodevelopment to 3 yrs. 
Provides measures of cognitive 
function: visual preference, 
attention, memory, 
sensorimotor, exploration, 
manipulation, and concept 
formation. Fine and gross motor 
development are also assessed. 
Administered by Outcomes 
Specialist. (C) 
Cognitive & Motor 
Scores Subtest 
Scaled Scores 
Pediatric Evaluation of 
Disability Inventory 
[47] (10 min) 
6mo and 12 mo 
The PEDI Mobility and Self-Care 
domains provide standardized 
assessments of skills appropriate 
from ages 6 months to 7.5 years. 
Administered by Outcomes 
Specialist or Research Study 
Staff. (P) 
Mobility and Self- 
Care Standard 
Scores 
Brief Infant Sleep 
Questionnaire [48] 
(5 min) 
1mo*, 6mo, 12mo 
The BISQ is a modified 
questionnaire that provides a 
general assessment of infant 
sleep behaviors. Administered by 
Outcomes Specialist or Research 
Study Staff. (P) 
General Sleep 
Assessments 
SOCIAL AND EMOTIONAL STATUS OF INFANT 
Bayley Social and 
Emotional Scale [45] 
(10 min) 
6mo and 12 mo 
The Bayley S&E measures social 
and emotional adjustment of 
infants and toddlers. 
Administered by Outcomes 
Specialist. (P) 
Composite Score 
PARENTAL INTELLECTUAL ABILITY AND PSYCHOLOGICAL STATUS 
Wechsler Abbreviated 
Scale of Intelligence 
[42] (20 min) 
1mo** 
The WASI II is a short and 
reliable measure of intelligence 
in clinical, psycho-educational, 
and research settings and is 
individually administered. Four 
subtests will be used to generate 
a FSIQ: Vocabulary, Block 
Design, Matrix Reasoning, and 
Similarities. Administered by 
Outcomes Specialist. (P) 
4-Factor IQ 
Brief Symptom 
Inventory-18 [41] (5 
min) 
1mo (baseline), 6mo, 
12mo 
The BSI provides a valid 
assessment of adult psychiatric 
status, including the domains of 
depression, anxiety, and 
somatization. Administered by 
Outcomes Specialist or Research 
Study Staff. (P) 
GSI Subtest T- 
Scores 
ENVIRONMENT AND FAMILY FUNCTION OF PARENT 
General Functioning 
Scale [40] (5 min) 
1mo (baseline), 6mo, 
12 mo 
The McFad is a subscale from 
McMaster Family Assessment 
Device (FAD).12-item scale is an 
overall measure of family 
functioning and has been shown 
to interact with illness severity 
Total Score 
(continued on next page) 
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subjects who participate in follow-up assessments on site, and monetary 
remuneration for subject’s time post hospital discharge for participation 
in the 1-mo maternal, and 6mo and 12mo infant developmental and 
maternal assessments. 
2.8. Data management 
Primary study data (including data obtained from EMR, interviews, 
and follow-up assessments) are collected and managed using Research 
Electronic Data Capture (REDCap) tools hosted at UMass [43,44]. 
REDCap is a secure, web-based software platform designed to support 
data capture for research studies that provides: 1) an intuitive interface 
for validated data capture; 2) audit trails for tracking data manipulation 
and export procedures; 3) automated export procedures for seamless 
data downloads to common statistical packages; and 4) procedures for 
data integration and interoperability with external sources [43,44]. To 
promote data quality, REDCap study forms include range checks for data 
values and check boxes for unknown and not-completed assessments to 
reduce data entry errors. 
Digitized data obtained from external acquisition systems (physio-
logic data, Embla N700, Broomfield, CO; actigraph data, Actiwatch 2, 
Philips Respironics, Murrysville, PA) are processed using respective 
proprietary software and specially-designed programs developed by our 
study team. The de-identified processed data are stored on encrypted, 
password-protected electronic data bases. De-identified data from the 
electronic data bases are imported into statistical programs (e.g., SAS 
Institute, Cary, NC; SPSS, Chicago, IL) for analysis. Quick Base is the 
platform used to store subject contact information for follow-up as-
sessments. These electronic storage databases comply with UMass data 
security guidelines and employ high security, controlled access points 
and automated incident detection and procedures to ensure secure 
infrastructure. Only investigators with IRB approval are assigned 
password-protected accounts in these environments. Data files will be 
archived as required by IRB and Institutional policies past the end of the 
study. 
2.9. Data safety and monitoring board (DSMB) 
The DSMB is made up of three experienced external investigators, 
including clinicians and a biostatistician, who provide oversight of the 
safety of the trial participants and of the conduct of the study. The Board 
was appointed by the study investigators with approval from the IRB and 
sponsoring agency. The Board reviews reports on safety, recruitment, 
and study conduct prepared by the trial biostatistician (BB), may request 
additional data/information (if necessary), and advises the trial lead-
ership regarding continuation/discontinuation of the study. 
The DSMB will meet at least twice per year and possibly more 
frequently if the speed of recruitment warrants it. The DSMB may 
request more frequent reports of selected information, such as recruit-
ment or adverse events, and, if one or more members requests, a meeting 
will be arranged as soon as possible. Minutes of the DSMB meetings and 
communications from the DSMB to the PI and to NIH will also be filed 
with the UMMS IRB. 
2.10. Outcomes 
The primary short-term clinical outcome is withdrawal severity 
quantified by withdrawal scores [27,35] (including max and means) and 
use of primary pharmacological agent (i.e., days treated and cumulative 
dose of morphine). Secondary short-term outcomes that will also pro-
vide an index of withdrawal severity throughout hospitalization are use, 
duration and cumulative dose of secondary/tertiary medications, ve-
locity of weight gain, and length of hospitalization. In addition, physi-
ologic data obtained from actigraphy and from the single sessions 
studies will provide a quantitative index of the physiology of withdrawal 
at different time points throughout the infant’s hospitalization. The 
study design also allows comparison of physiologic and actigraphy dif-
ferences between intervals of SVS ON and SVS OFF among infants 
assigned to SVS, and among infants assigned to TAU (i.e., SVS OFF). 
The primary longitudinal outcome is infant neurodevelopment in the 
first year of life, measured by the Bayley III Scales of Infant Development 
[45] at 6 mos and 12 mos of age. These tests include well-established 
and validated measures of infant development, intelligence, and neu-
ropsychological function and assess five functional domains: attention 
and executive function, language, sensorimotor function, visuospatial 
processing, and memory and learning [46]. Secondary long-term out-
comes that will assess development in the first year of life include 
mobility skills [47], fine and gross motor development, social and 
emotional adjustment [45], and sleep behaviors [48]. See Table 1 for a 
list and timing of the longitudinal assessments. 
2.10.1. Potential confounders, Co-factors and effect modifiers 
We will obtain a comprehensive data set on the infant and mother, 
including maternal medical history, drug use and medications 
throughout pregnancy, chronic health and psychiatric conditions, 
pregnancy and delivery complications, and intellectual, social and 
economic factors (e.g., personal relationships, education level, living 
arrangements, work status). We will also obtain daily cares of infant 
throughout hospitalization including feed type (formula or breast milk) 
and feed route (bottle/gavage or breast-fed) and medications. 
Computerized bedside log (Fig. 3) will provide an estimate of how 
many hours per day infants are held by caregivers, placed in hospital- 
issued motorized seats, or lying in crib (subsequently calculated to 
assess overall duration with and without SVS). This log data will also 
allow for comparisons between infant movement activity (actigraphy), 
index of irritability, when the infant is in the crib with SVS ON compared 
to SVS OFF. 
Follow-up phone assessments will provide information about envi-
ronment (e.g., biological family or placed in foster care), housing (e.g., 
shelter or private home), infant sleep behaviors, and socialization and 
supplemental care (daycare; Early Intervention). 
2.11. Statistical approach 
2.11.1. Sample size/feasibility 
We will recruit 230 infant-mother dyads (460 subjects) over a 5-year 
period. At the time of anticipated start of enrollment (2016), UMass had 
approximately 4000 deliveries per year and UPitt had approximately 
10,000 deliveries per year, with estimated 2–3% newborns diagnosed 
Table 1 (continued ) 
Task (time) 
Testing Age 
Description and Respondent 
[Child (C) or Parent (P)] 
Key Variables 
and pediatric outcome studies 
using the FAD. Completed at 
study entry, 6mo, and 12 month 
evaluation to track changes in 
family function over time. 
Administered by Outcomes 
Specialist or Research Study 
Staff. (P) 
Note to Table 1: 1mo, 6mo, and 12mo time points are approximate testing pe-
riods. Assessments will primarily be administered by Outcomes Specialist in the 
outpatient clinic/office or at home visits, except in some instances: 
1) BSI and McFad (baseline) questionnaires may be administered in hospital by 
research study staff to obtain baseline assessment while the infant and/or 
mother are still in hospital (may be performed by Outcomes Specialist at 1mo 
outpatient visit if unable to administer while in hospital). 
2) *GOSE-E Peds and BISQ will not be performed at the 1-month time point if the 
infant is hospitalized at timeframe of testing period; we anticipate all infants will 
be discharged before the 6mos assessments. 
3) **WASI II may be administered anytime throughout the study period by 
Outcomes Specialist. 
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with NAS due to opioid exposure at each site (~90 and 250 per year, 
respectively). At UMass, on average 75–80% of the opioid-exposed 
newborns typically required prolonged hospitalization for pharmaco-
logical management of NAS (primary morphine) and 20–25% were 
discharged without pharmacological treatment. At UPitt ~60% of the 
opioid-exposed newborns required prolonged hospitalization for phar-
macological management of NAS (primary morphine) with 40% dis-
charged without pharmacological treatment. 
Based on conservative estimate (i.e., inability to obtain informed 
consent in ~50% potential candidates due to parent inaccessibility, lack 
of interest and custodial issues related to incarceration), we anticipated 
a sufficient subject pool of ~45 opioid-exposed newborns/year at UMass 
and ~125/year at UPitt. At UMass we estimate to enroll 25 infants/year 
over a four year period (100 total) with approximately 75% (19 infants/ 
yr) requiring prolonged hospitalization for pharmacological manage-
ment (estimate 75 treated in the NICU over 4 years). At UPitt we expect 
to enroll ~22 infants in the first year and ~36/year in years 2–4 (130 
total) with approximately 60% (78 infants) requiring prolonged hospi-
talization for pharmacological management over the course of the study. 
2.11.2. Power calculations 
We anticipate sufficient sample size to detect clinically meaningful 
differences with 90% power, described below:  
(1) In hospital short-term clinical outcomes. Given that withdrawal 
severity drives and guides pharmacological management, power 
calculations for short-term in clinical outcomes assessments were 
based on the commonly used Finnegan NAS score [35], the 
withdrawal assessment tool used to assess severity of withdrawal 
at both sites. Based on Nayeri [49] and our own data (Finnegan 
NAS score in opioid-exposed infants; SD of 2.0–2.5 [29]), 
assuming a standard t-test with a two-sided alpha level of 0.05 for 
the unadjusted comparison of the Finnegan scores using a con-
servative standard deviation (SD = 2.5), we estimated a sample 
size of 115/group can detect a difference of 1.1 with 90% power. 
Taking into account repeated measures of the Finnegan NAS 
score, assuming intra-infant correlations of 0.5–0.7, we will have 
90% power to detect a difference of 0.80–0.95 in a mixed effects 
model for the overall (i.e., across time) treatment group coeffi-
cient. With a mixed effects model, we will also add covariates as 
described above to determine an adjusted treatment effect. We 
expect that this model may have even more power than described 
here due to the partitioning of the overall variance among the 
covariates. Because infants are hospitalized and under observa-
tion until release, we expect only minimal attrition and loss of 
information.  
(2) In-hospital physiologic outcomes. Using movement duration as a 
primary outcome to power the physiologic single sessions based 
on our preliminary data in 26 NAS infants [29] (OFF: mean 40% 
condition time, SD = 10%; ON: mean 26% condition time, SD =
9%) and assuming a two-sided paired t-test at alpha = 0.05 for the 
unadjusted treatment effect, we estimated 25 infants per group 
will give us 90% power to detect a reduction of 7% in movement 
between the two treatment groups (a relative reduction of about 
20% from 40% in OFF to 33% in ON with a conservative SD of 
10%).  
(3) Post-discharge longitudinal developmental outcomes. For the 
longitudinal follow-up outcomes, power analysis was calculated 
for cognitive function at 12-months using Bayley-III Scales of 
Infant Development [45]. We anticipated an attrition rate of 
~40% in the 1-year follow-up assessments. Assuming a sample 
size of 60 infants/group at 12 months of age with a two-sided 
standard t-test at alpha = 0.05 and SD of 14 for the Bayley-III 
Cognitive Composite Scale [50], we will have 90% power to 
detect a difference of 8.5 (or about a 12% difference) between the 
two groups. The other Bayley scales have similar SDs, so the 
results will be similar. For a longitudinal analysis of the Bayley-III 
Cognitive Composite Scale over the follow-up visits (6 and 12 
months of age), we will use a mixed effects model as above with 
months of age as the time metric in the model. Assuming the same 
sample size with intra-child correlations of 0.5–0.7 for a mixed 
effects model with a two-sided test for the treatment group co-
efficient at alpha = 0.05, we estimated we will have 90% power 
to detect a treatment effect of 6.8–7.4 (depending on the corre-
lation) using the treatment group coefficient. We can also add 
covariates to this model to estimate an adjusted treatment effect. 
2.11.3. Statistical analyses  
(1) In hospital short-term clinical outcomes. Descriptive statistics 
will be calculated (means/SD or median/IQR) by assignment 
group (SVS or TAU) of outcome variables (e.g., withdrawal 
scores, pharmacotherapy, duration and cumulative dose, move-
ment activity indexed by actigraphy). Because infants will be 
repeatedly observed and measured, initial analyses comparing 
outcomes between the groups will be conducted using standard 
approaches assuming a normal distribution (i.e., two-sample t- 
test) or using non-parametric alternatives if assumption of a 
normal distribution is not appropriate (i.e., Mann-Whitney U 
Test). We will use mixed effect models to analyze the repeated 
measures over time. These models will estimate the trajectory of 
outcomes over time within each treatment group as affected by 
condition and other factors of interest. Treatment group will be 
considered as fixed effect in the models, with other factors 
considered to be either fixed or random effects, depending on the 
nature of the factor. Examples of factors of interest include: study 
site; drug exposure (e.g., opioid type such as prescribed mainte-
nance therapy, other prescribed medication, and illicit substance; 
with or without poly-drug use), demographic data (e.g., gender, 
gestational age, birth weight, birth head circumference; infant 
race as provided by the biological mother), and feed type/route 
(formula or breast milk/bottle breast-fed). Comprehensive his-
tories from medical record and questionnaires will allow us to 
examine the influence of additional variables. Factors of interest 
will be included in the model as appropriate and interactions with 
treatment group will be tested as well. The interactions will 
indicate whether the treatment effect is the same across sub-
groups. Additional analyses to identify groups of infants who do 
particularly well (or poorly) with SVS will be conducted using 
latent class techniques, such as cluster analysis (for continuous 
variables) or latent class analysis (for discrete variables).  
(2) In-hospital physiologic outcomes. Study design allows systematic 
quantification of condition effects on breathing (inter-breath 
variance and respiratory rate), cardiac rhythm (R-R variance and 
heart rate), movement activity (frequency and duration), blood- 
oxygen levels, and skin temperature. Histogram of frequency- 
bands of cardiac, respiratory and movement incidents will be 
determined. Mixed effects models will be used to examine if SVS, 
within SVS-assigned infants, and between SVS and TAU groups: 
1) Decreases irritability indexed by movement frequency and 
duration; 2) Improves cardio/respiratory activity; e.g., reduces 
bradycardia/bradypnea, tachycardia/tachypnea and increases 
incidents of eucardia/eupnea; and 3) Reduces other NAS symp-
toms: e.g., temperature; oxygenation.  
(3) Post-discharge longitudinal developmental outcomes. We will use a 
general linear model approach to analyze outcomes over one 
year, using the same model building strategies described in (1) 
above. Some outcomes, such as the Bayley-III scales [45], are 
collected at multiple follow-up visits, so we will use mixed effects 
models to estimate treatment effect over time and to adjust for 
other covariates. Impairment is determined based on a fairly 
extensive neurobehavioral test battery, but the component test 
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scores are highly correlated. To control for error that results from 
this correlation, we will reduce the number of tests by evaluating 
the domain or summary scores from the various instruments and 
use the approach of Ingraham and Aiken [51] to determine how 
many deviant scores are required to identify an infant as 
impaired. This approach calculates the criteria for abnormality 
when employing batteries of multiple tests by generating prob-
ability curves for exceeding cut-off criteria by chance given 
certain criteria (e.g., an expectation that one group will show a 
decrement). This type of analysis will allow us to look at rate of 
impairment in young children with opioid exposure and assess 
whether SVS compared to TAU reduces likelihood of impairment. 
2.12. Registration and trial status 
This protocol was developed according to the 2013 Standard Protocol 
Items: Recommendations for Interventional Trials (SPIRIT) checklist [52]. 
The reporting of the results will follow the 2017 consolidated standards 
of reporting trials (CONSORT) [53] for reporting a randomized trial 
assessing non-pharmacological treatments. The trial was registered 
within ClinicalTrials.gov (NCT02801331) on June 15, 2016. Recruit-
ment began March 2017 at UMass and August 2017 at UPitt. In-person 
studies (in-hospital bedside and follow-up) were halted due to Covid-19 
Institutional and IRB requirements. It is anticipated that recruitment will 
be completed by approximately December 31, 2020. 
3. Discussion 
Despite rapidly rising rates of NAS due to opioid exposure in new-
borns over the last decade [1–3,5], there has been little advancement in 
improving diagnosis and treatment strategies [15]. The aim of this trial 
is to assess the effectiveness of SVS for reducing drug withdrawal in 
opioid-exposed newborns and for improving long-term developmental 
outcomes. The hospital setting provides a unique opportunity for 
studying the onset, duration, and severity of symptoms and dysregulated 
behaviors associated with NAS, and for advancing new strategies that 
improve short-term clinical outcomes and promote healthy neonatal 
development. In this clinical trial, withdrawal will be assessed by several 
measures, including standard clinical withdrawal-severity scores, 
physiologic recordings, and actigraphy. In-hospital outcomes (e.g., 
withdrawal scores, cumulative morphine, length of treatment, velocity 
of weight gain) and 6-month and 12-month follow-up (masked neuro-
developmental assessments) will be compared between infants assigned 
the SVS mattress intervention and infants assigned the hospital mattress, 
with the overarching goal to optimize diagnosis and management of 
opioid-exposed newborns. 
To assess risk factors that may be associated with NAS, this proposal 
is designed to include multi-parametric data such as demographics (e.g., 
gender, race, gestational age, weight) and drug history (e.g., single 
opioid versus opioid plus other drug exposure). Although the general 
symptoms and physical signs of withdrawal tend to be relatively similar 
regardless of drug/s of exposure, the onset, duration and severity of 
opioid withdrawal are highly variable and unpredictable [10,12,54,55]. 
In this trial, we will obtain comprehensive medical information on the 
biological mother and infant, including toxicology reports and daily 
EMR data regarding infant withdrawal scores, medications, feeds and 
weight that will allow us to track severity of withdrawal, course of 
treatment, and clinical outcomes throughout hospitalization. We will 
also obtain detailed history of drug report from interview with the 
biological mother, which may provide unique insight on outcomes 
related to type and timing of drug exposures throughout the prenatal 
period. 
It is well documented that fetal exposure to opioids commonly dis-
rupts central, autonomic, vasomotor and gastrointestinal function in the 
newborn [7,12,13,17,36,56,57]. However, there is a paucity of research 
on the physiology that demarcates neonatal drug withdrawal in the first 
weeks of life. Furthermore, despite lack of well-defined characterization 
of physiologic withdrawal, potent analgesics (e.g., morphine, metha-
done), central-nervous system depressants (e.g., phenobarbital) and 
hypertensives (e.g., clonidine) with well-documented long-term neuro-
developmental consequences are commonly used to treat opioid with-
drawal in neonates [23,36,54,58–60]. Complementary, 
non-pharmacological interventions are needed to treat NAS and 
reduce use of these intoxicating medications. In this comprehensive 
clinical trial, we will study physiologic activity (e.g., cardiac, respira-
tory, blood-oxygenation, temperature, limb movement) in a cohort of 
infants at around 5–7 and 12–14 days of life. This data will provide 
objective quantifiable measures of physiologic withdrawal among 
newborns at two consistent time periods and assess whether physiologic 
indicators (e.g., cardio-respiratory pathophysiological instabilities; 
excessive movement) are reduced with SVS. Cofactors that may optimize 
the effectiveness, or exacerbate withdrawal, will also be assessed. 
A major aim of this proposal is to test the hypothesis that SVS reduces 
NAS morbidities and enhances neurobehavioral development 
throughout the first year of life. There are very few longitudinal studies 
on neurobehavioral consequences of intrauterine opioid exposure 
[60–62]. Those available have conflicting results that can be attributed 
to variations in poly-substance use including type, quantity/dose and 
duration, maternal psychiatric morbidity, prenatal care and obstetrical 
complications, homogenous and small populations of subjects, type and 
duration of treatment including pharmacological interventions and 
mother-child interactions, quality of the assessments and use of different 
neurobehavioral tests at different ages [60,63]. Neurobehavioral out-
comes in neonates exposed to drugs are also likely influenced by 
socio-demographic, biological, health and economic factors [60,63] Our 
testing measures take these variables into account (see Table 1) [40,63]. 
Because opioid-exposed infants are susceptible to poor outcomes due to 
biological and environmental factors, it is especially important to 
develop strategies that provide early intervention to promote healthy 
development. An important goal of this project is to determine whether 
early therapy with SVS puts at-risk infants on a trajectory for improved 
outcomes compared to infants receiving TAU. We will follow infants 
bi-monthly via caregiver report and at in-person assessments by trained 
outcomes specialists at 6-mos and 12-mos to help differentiate among 
short and longer-term deficits. 
This project brings together established investigators and expert 
clinicians to conduct a dual-site, prospective longitudinal study in 
newborns exposed to opioids in utero. The advantage of studying infants 
at two sites is that we will be able to test the effectiveness of SVS as a 
therapeutic intervention in a large population of infants, encompassing a 
wider range of demographics, drugs of exposure and standard-care 
practices. SVS will be initiated shortly after birth and administered 
daily throughout hospitalization. Findings from this trial will improve 
understanding of withdrawal in opioid-exposed newborns, and will 
determine whether SVS, compared to TAU, reduces severity of NAS, 
attenuates the need for pharmacotherapy, and improves physiologic 
function with associated improved long-term cognitive, behavioral and 
health outcomes. 
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